A new combination therapy of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE® (lazertinib) has improved overall survival statistically and clinically significantly when compared to osimertinib, the current standard of care for patients with EGFR-mutated non-small cell lung cancer (NSCLC). This is a significant development for the treatment of lung cancer, according to Johnson & Johnson. The Phase 3 MARIPOSA study’s Asia cohort provided the findings.
This is a significant development, especially for patients in Asia, where the majority of EGFR-mutated NSCLC cases occur. Compared to 10 to 15 percent in Europe and the US, 30 to 40 percent of patients in Asia have this kind of lung cancer. According to the trial findings, patients treated with the novel combination are expected to have a median overall survival of more than four years, which is a full year longer than that of patients treated with osimertinib alone.
Read More: Johnson & Johnson Launches MENTOR™ MemoryGel™ Breast Implants for Reconstruction Patients
1,074 patients participated in the randomized, Phase 3 clinical trial known as the MARIPOSA research, which aimed to compare the effectiveness of amivantamab plus lazertinib vs osimertinib as a first-line treatment. Although progression-free survival (PFS) was the main outcome, the oncology community has been quite excited about the improvement in overall survival (OS), which is a crucial secondary outcome.
No new safety issues were observed, and the new medicine combination’s safety profile was judged to be in line with earlier investigations. The business points out that preventative activities can be taken to manage any side effects, like skin and infusion-related reactions.
Overall survival is the most meaningful measure of progress, and the MARIPOSA Asia cohort results reinforce the role of therapeutic innovations like amivantamab plus lazertinib in the first-line setting,
With its triple mode of action targeting EGFR and MET while also activating immune cells, amivantamab plus lazertinib addresses resistance that often limits tyrosine kinase inhibitor based therapy and delivers durable survival. These findings, with a median overall survival projected beyond four years, mark an important milestone for patients across Asia.
Anthony Elgamal
Clinical practice is anticipated to be significantly impacted by the encouraging results from the MARIPOSA Asia cohort. Amivantamab and lazertinib together have already been approved for the first-line therapy of EGFR-mutated non-small cell lung cancer in a number of nations and regions, including the US and Europe. Its status as a new standard of care is probably going to be further cemented by these recent findings.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
NSCLC is the most prevalent type of lung cancer, which continues to be a major cause of cancer-related mortality globally. Patients with certain genetic mutations causing their cancer now have new hope thanks to the development of targeted medicines like the combination of amivantamab and lazertinib, which promises longer and higher-quality lives.
At a forthcoming medical conference, the complete findings of the MARIPOSA Asia cohort research will be revealed, offering more information on the magnitude of the survival benefit and its implications for the treatment of lung cancer in the future.
Last Modified:
Graduated from the University of Kerala'20 with B.Sc. Botany & Biotechnology. Post-graduation in Biotechnology from the University of Kerala'22. Internship experience in Cancer Research.
